基于法国队列的儿科 NT-proBNP 和 Galectin-3 参考值。

IF 3.2 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY
Victor Gravrand , Corentin S. Lefebvre , Fatma Hamza , Thibaud Della-Negra , Vincent Coyaud , Axelle Vasseur , Carole Hennequin , Valérie Nivet-Antoine , Damien Schaffner
{"title":"基于法国队列的儿科 NT-proBNP 和 Galectin-3 参考值。","authors":"Victor Gravrand ,&nbsp;Corentin S. Lefebvre ,&nbsp;Fatma Hamza ,&nbsp;Thibaud Della-Negra ,&nbsp;Vincent Coyaud ,&nbsp;Axelle Vasseur ,&nbsp;Carole Hennequin ,&nbsp;Valérie Nivet-Antoine ,&nbsp;Damien Schaffner","doi":"10.1016/j.cca.2024.119925","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>In pediatric cardiology, the fact that some new biomarkers have assay-specific normal values has to be considered for correct clinical decisions. The current study aimed to provide age-adjusted normative values for NT-proBNP and Galectin-3 using the Abbott immunoassay system from a prospective French pediatric cohort sera collection and to validate our data for NT-proBNP on a second retrospective cohort.</p></div><div><h3>Methods</h3><p>We analyzed 283 consecutive samples for NT-proBNP and 140 samples for Galectin-3 collected from apparently healthy children (0–18 years) with outpatient treatment at our institution (Hôpital Necker-Enfants malades, Paris, France) during 24 months.</p></div><div><h3>Results</h3><p>For NT-proBNP and Galectin-3, we establish four age partitions, respectively two (&lt;2 years / &gt;2 years) and establish upper reference values and their 90 % CI for each biomarker (Galectin-3 (ng/mL): 56 [44–70] / 26 [23–29]). We evaluated the diagnostic performance of our upper reference values of NT-proBNP on a retrospective cohort (n = 428) with positive predictive value of 0.92.</p></div><div><h3>Conclusions</h3><p>Using Abbott immunoassay system, we report age-specific reference values for NT-proBNP and for the first time for Galectin-3 in a healthy French pediatric cohort. These data call for larger cohort studies to define more robustly percentiles and diagnostic performance for NT-proBNP.</p></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pediatric reference values of NT-proBNP and Galectin-3 based on a French cohort\",\"authors\":\"Victor Gravrand ,&nbsp;Corentin S. Lefebvre ,&nbsp;Fatma Hamza ,&nbsp;Thibaud Della-Negra ,&nbsp;Vincent Coyaud ,&nbsp;Axelle Vasseur ,&nbsp;Carole Hennequin ,&nbsp;Valérie Nivet-Antoine ,&nbsp;Damien Schaffner\",\"doi\":\"10.1016/j.cca.2024.119925\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>In pediatric cardiology, the fact that some new biomarkers have assay-specific normal values has to be considered for correct clinical decisions. The current study aimed to provide age-adjusted normative values for NT-proBNP and Galectin-3 using the Abbott immunoassay system from a prospective French pediatric cohort sera collection and to validate our data for NT-proBNP on a second retrospective cohort.</p></div><div><h3>Methods</h3><p>We analyzed 283 consecutive samples for NT-proBNP and 140 samples for Galectin-3 collected from apparently healthy children (0–18 years) with outpatient treatment at our institution (Hôpital Necker-Enfants malades, Paris, France) during 24 months.</p></div><div><h3>Results</h3><p>For NT-proBNP and Galectin-3, we establish four age partitions, respectively two (&lt;2 years / &gt;2 years) and establish upper reference values and their 90 % CI for each biomarker (Galectin-3 (ng/mL): 56 [44–70] / 26 [23–29]). We evaluated the diagnostic performance of our upper reference values of NT-proBNP on a retrospective cohort (n = 428) with positive predictive value of 0.92.</p></div><div><h3>Conclusions</h3><p>Using Abbott immunoassay system, we report age-specific reference values for NT-proBNP and for the first time for Galectin-3 in a healthy French pediatric cohort. These data call for larger cohort studies to define more robustly percentiles and diagnostic performance for NT-proBNP.</p></div>\",\"PeriodicalId\":10205,\"journal\":{\"name\":\"Clinica Chimica Acta\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinica Chimica Acta\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0009898124021788\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898124021788","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:在儿科心脏病学中,为了做出正确的临床决策,必须考虑到一些新的生物标志物具有检测特异性正常值这一事实。本研究旨在使用雅培免疫测定系统从法国前瞻性儿科队列血清收集中提供经年龄调整的 NT-proBNP 和 Galectin-3 正常值,并在第二个回顾性队列中验证我们的 NT-proBNP 数据:方法:我们分析了连续采集的283份NT-proBNP样本和140份Galectin-3样本,这些样本均来自24个月内在我院(法国巴黎Necker-Enfants malades医院)接受门诊治疗的表面健康儿童(0-18岁):对于 NT-proBNP 和 Galectin-3,我们建立了四个年龄分区,分别为两个(2 岁),并为每种生物标志物(Galectin-3(纳克/毫升):56 [44-70] / 26 [23-29])建立了上限参考值及其 90 % CI。我们在一个回顾性队列(n = 428)中评估了 NT-proBNP 上限参考值的诊断性能,其阳性预测值为 0.92:我们使用雅培免疫测定系统首次报告了法国健康儿童队列中 NT-proBNP 和 Galectin-3 的特定年龄参考值。这些数据要求进行更大规模的队列研究,以更准确地定义 NT-proBNP 的百分位数和诊断性能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pediatric reference values of NT-proBNP and Galectin-3 based on a French cohort

Background

In pediatric cardiology, the fact that some new biomarkers have assay-specific normal values has to be considered for correct clinical decisions. The current study aimed to provide age-adjusted normative values for NT-proBNP and Galectin-3 using the Abbott immunoassay system from a prospective French pediatric cohort sera collection and to validate our data for NT-proBNP on a second retrospective cohort.

Methods

We analyzed 283 consecutive samples for NT-proBNP and 140 samples for Galectin-3 collected from apparently healthy children (0–18 years) with outpatient treatment at our institution (Hôpital Necker-Enfants malades, Paris, France) during 24 months.

Results

For NT-proBNP and Galectin-3, we establish four age partitions, respectively two (<2 years / >2 years) and establish upper reference values and their 90 % CI for each biomarker (Galectin-3 (ng/mL): 56 [44–70] / 26 [23–29]). We evaluated the diagnostic performance of our upper reference values of NT-proBNP on a retrospective cohort (n = 428) with positive predictive value of 0.92.

Conclusions

Using Abbott immunoassay system, we report age-specific reference values for NT-proBNP and for the first time for Galectin-3 in a healthy French pediatric cohort. These data call for larger cohort studies to define more robustly percentiles and diagnostic performance for NT-proBNP.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinica Chimica Acta
Clinica Chimica Acta 医学-医学实验技术
CiteScore
10.10
自引率
2.00%
发文量
1268
审稿时长
23 days
期刊介绍: The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信